Giant cell arteritis successfully treated with subcutaneous tocilizumab monotherapy.
Giant cell arteritis
Large vessel vasculitis
Monotherapy
Polymyalgia rheumatica
Tocilizumab
Journal
Rheumatology international
ISSN: 1437-160X
Titre abrégé: Rheumatol Int
Pays: Germany
ID NLM: 8206885
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
23
07
2022
accepted:
19
09
2022
pubmed:
25
9
2022
medline:
3
3
2023
entrez:
24
9
2022
Statut:
ppublish
Résumé
Glucocorticoid remains the mainstay for treatment of large vessel vasculitis (LVV) including giant cell arteritis (GCA); however, the disease affects the elderly for whom the adverse effects of glucocorticoid are problematic. Recently, some reports have suggested that intravenous tocilizumab (TCZ) monotherapy is effective for this disease. To date, it remains unknown whether subcutaneous TCZ monotherapy is also effective. Here, we present a first case of GCA successfully treated with subcutaneous TCZ monotherapy. A 75-year-old woman presented with shoulder and hip pain. She was diagnosed with polymyalgia rheumatica (PMR) and treated with low-dose prednisolone (15 mg daily); however, she discontinued glucocorticoid therapy at her discretion due to the psychiatric adverse effect (cognitive dysfunction). Seven months later, her shoulder and hip pain relapsed. Furthermore,
Identifiants
pubmed: 36152056
doi: 10.1007/s00296-022-05217-x
pii: 10.1007/s00296-022-05217-x
doi:
Substances chimiques
tocilizumab
I031V2H011
Fluorodeoxyglucose F18
0Z5B2CJX4D
Glucocorticoids
0
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
545-549Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Koster MJ, Matteson EL, Warrington KJ (2018) Large-vessel giant cell arteritis: diagnosis, monitoring and management. Rheumatology (Oxford) 57:ii32–ii42. https://doi.org/10.1093/rheumatology/kex424
doi: 10.1093/rheumatology/kex424
pubmed: 29982778
Weyand CM, Watanabe R, Zhang H, Akiyama M, Berry GJ, Goronzy JJ (2019) Cytokines, growth factors and proteases in medium and large vessel vasculitis. Clin Immunol 206:33–41. https://doi.org/10.1016/j.clim.2019.02.007
doi: 10.1016/j.clim.2019.02.007
pubmed: 30772599
pmcid: 6693995
Akiyama M, Ohtsuki S, Berry GJ, Liang DH, Goronzy JJ, Weyand CM (2021) Innate and adaptive immunity in giant cell arteritis. Front Immunol 11:621098. https://doi.org/10.3389/fimmu.2020.621098
doi: 10.3389/fimmu.2020.621098
pubmed: 33717054
pmcid: 7947610
Dunstan E, Lester SL, Rischmueller M, Dodd T, Black R, Ahern M et al (2014) Epidemiology of biopsy-proven giant cell arteritis in South Australia. Intern Med J 44:32–39. https://doi.org/10.1111/imj.12293
doi: 10.1111/imj.12293
pubmed: 24118799
Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D et al (2017) Trial of tocilizumab in giant-cell arteritis. N Engl J Med 377:317–328. https://doi.org/10.1056/NEJMoa1613849
doi: 10.1056/NEJMoa1613849
pubmed: 28745999
Saito S, Okuyama A, Okada Y, Shibata A, Sakai R, Kurasawa T et al (2020) Tocilizumab monotherapy for large vessel vasculitis: results of 104-week treatment of a prospective, single-centre, open study. Rheumatology (Oxford) 59:1617–1621. https://doi.org/10.1093/rheumatology/kez511
doi: 10.1093/rheumatology/kez511
pubmed: 31665468
Seitz M, Reichenbach S, Bonel HM, Adler S, Wermelinger F, Villiger PM (2011) Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly 141:w13156
pubmed: 21243547
Pazzola G, Padovano I, Boiardi L, Versari A, Pipitone N, Catanoso M et al (2013) Tocilizumab in glucocorticoid-naïve large-vessel vasculitis. Clin Exp Rheumatol 31:S59-61
pubmed: 23306184
Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409–1417. https://doi.org/10.1007/s00296-011-1999-3
doi: 10.1007/s00296-011-1999-3
pubmed: 21800117
Grayson PC, Alehashemi S, Bagheri AA, Civelek AC, Cupps TR, Kaplan MJ et al (2018) 18 F-Fluorodeoxyglucose-positron emission tomography as an imaging biomarker in a prospective, longitudinal cohort of patients with large vessel vasculitis. Arthr Rheumatol 70:439–449. https://doi.org/10.1002/art.40379
doi: 10.1002/art.40379
Dasgupta B, Cimmino MA, Maradit-Kremers H, Schmidt WA, Schirmer M, Salvarani C et al (2012) 2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis 71:484–492. https://doi.org/10.1136/annrheumdis-2011-200329
doi: 10.1136/annrheumdis-2011-200329
pubmed: 22388996
Sandovici M, Geest NVD, Sleen YV, Brouwer E (2022) Need and value of targeted immunosuppressive therapy in giant cell arteritis. RMD Open 8:e001652. https://doi.org/10.1136/rmdopen-2021-001652
doi: 10.1136/rmdopen-2021-001652
pubmed: 35149602
pmcid: 8845325
Pipitone N, Muratore F, Tamagnini I, Cavazza A, Cimino L, Boiardi L et al (2019) Interleukin-6 expression in inflamed and non-inflamed temporal arteries from patients with giant cell arteritis. Clin Exp Rheumatol 37:98–103
pubmed: 31025922
Grossman C, Yassin N, Avivi C, Bornstein G, Ben-Zvi I, Barshack I (2019) Cytokine expression in temporal arteries: comparative analysis between patients with biopsy-positive giant cell arteritis, biopsy-negative giant cell arteritis and biopsy-negative without arteritis. Clin Exp Rheumatol 37:122–129
pubmed: 31162032
Berger CT, Rebholz-Chaves B, Recher M, Manigold T, Daikeler T (2019) Serial IL-6 measurements in patients with tocilizumab-treated large-vessel vasculitis detect infections and may predict early relapses. Ann Rheum Dis 78:1012–1014. https://doi.org/10.1136/annrheumdis-2018-214704
doi: 10.1136/annrheumdis-2018-214704
pubmed: 30670375
Quinn KA, Dashora H, Novakovich E, Ahlman MA, Grayson PC (2021) Use of 18F-fluorodeoxyglucose positron emission tomography to monitor tocilizumab effect on vascular inflammation in giant cell arteritis. Rheumatology (Oxford) 60:4384–4389. https://doi.org/10.1093/rheumatology/keaa894
doi: 10.1093/rheumatology/keaa894
pubmed: 33369678
Quinn KA, Grayson PC (2019) The role of vascular imaging to advance clinical care and research in large-vessel vasculitis. Curr Treatm Opt Rheumatol 5:20–35. https://doi.org/10.1007/s40674-019-00114-0
doi: 10.1007/s40674-019-00114-0
pubmed: 31598465
pmcid: 6784843
Akiyama M, Kaneko Y, Takeuchi T (2020) Tocilizumab in isolated polymyalgia rheumatica: a systematic literature review. Semin Arthr Rheum 50:521–525. https://doi.org/10.1016/j.semarthrit.2019.12.005
doi: 10.1016/j.semarthrit.2019.12.005
Akiyama M, Kaneko Y, Takeuchi T (2020) Response to a letter to the editor entitled “is tocilizumab as efficient as steroids early in polymyalgia rheumatica?” Semin Arthr Rheum 50:890. https://doi.org/10.1016/j.semarthrit.2020.07.001
doi: 10.1016/j.semarthrit.2020.07.001
Adler S, Reichenbach S, Gloor A, Yerly D, Cullmann JL, Villiger PM (2019) Risk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis. Rheumatology 58:1639–1643. https://doi.org/10.1093/rheumatology/kez091
doi: 10.1093/rheumatology/kez091
pubmed: 30915462